TIDMHCM

RNS Number : 2982R

Hutchison China Meditech Limited

29 June 2020

Blocklisting Six Monthly Return

London: Monday, June 29, 2020 : Hutchison China MediTech Limited ("Chi-Med" or the "Company") (AIM/Nasdaq: HCM) announces the following blocklisting six monthly return:

 
1.   Name of applicant:            Hutchison China MediTech Limited 
2.   Name of scheme:               (a)  Share Option Scheme conditionally adopted 
                                         by Hutchison China MediTech Limited 
                                         in 2005 ("2005 HCML Share Option Scheme") 
                                   (b)  Share Option Scheme conditionally adopted 
                                         by Hutchison China MediTech Limited 
                                         in 2015 ("2015 HCML Share Option Scheme") 
3.   Period of return:             From December 29, 2019 to June 28, 2020 
4.   Balance under scheme          (a)        2005 HCML Share Option Scheme: 1,738,910 
      from previous return:                    ordinary shares of US$0.1 each 
                                   (b)        2015 HCML Share Option Scheme: 23,130,970 
                                               ordinary shares of US$0.1 each 
5.   The amount by which           (a)  2005 HCML Share Option Scheme: Nil 
      the block scheme has 
      been increased, if 
      the scheme has been 
      increased since the 
      date of the last return: 
                                   (b)  2015 HCML Share Option Scheme: Nil 
6.   Number of securities          (a)  2005 HCML Share Option Scheme: Nil 
      issued/allotted under 
      scheme during period: 
                                   (b)  2015 HCML Share Option Scheme: Nil 
7.   Balance under scheme          (a)  2005 HCML Share Option Scheme: 1,738,910 
      not yet issued/allotted            ordinary shares of US$0.1 each 
      at end of the period: 
                                   (b)  2015 HCML Share Option Scheme: 23,130,970 
                                         ordinary shares of US$0.1 each 
8.   Number and class of           25,198,880 ordinary shares of US$0.1 each 
      securities originally         admitted on June 17, 2019 ( to replace 
      listed and the date           the Company's previous block admission 
      of admission:                 schemes following the Company's share subdivision 
                                    which took effect on May 30, 2019) 
 
 
 
 
9.   Total number of securities    690,574,765 ordinary shares of US$0.1 each 
      in issue at the end 
      of the period: 
Name of contact:                   Christian Hogg 
Address of contact:                Level 18, The Metropolis Tower, 10 Metropolis 
                                    Drive, Hung Hom, Kowloon, Hong Kong 
Telephone number of contact:       +852 2121 8200 
 

About Chi-Med

Chi-Med (Nasdaq/AIM: HCM) is an innovative biopharmaceutical company committed, over the past twenty years, to the discovery and global development of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has a portfolio of eight cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. For more information, please visit: www.chi-med.com .

CONTACTS

 
Investor Enquiries 
  Mark Lee, Senior Vice President                            +852 2121 8200 
  Annie Cheng, Vice President                                +1 (973) 567 3786 
 
Media Enquiries 
  Americas - Brad Miles, Solebury Trout                      +1 (917) 570 7340 (Mobile) 
                                                              bmiles@troutgroup.com 
  Europe - Ben Atwell / Alex Shaw, FTI Consulting            +44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 
                                                             545 055 (Mobile) 
                                                             Chi-Med@fticonsulting.com 
  Asia - Joseph Chi Lo / Zhou Yi, Brunswick                  +852 9850 5033 (Mobile), jlo@brunswickgroup.com / +852 97 
                                                             83 6894 (Mobile), y zhou@brunswickgroup.com 
 
Nominated Advisor 
  Freddy Crossley / Atholl Tweedie, Panmure Gordon (UK) 
   Limited                                                   +44 (20) 7886 2500 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

BLRUWOARRKUNUUR

(END) Dow Jones Newswires

June 29, 2020 02:00 ET (06:00 GMT)

Hutchison China Meditech (LSE:0J7G)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Hutchison China Meditech Charts.
Hutchison China Meditech (LSE:0J7G)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Hutchison China Meditech Charts.